Nachrichten zur Biogen Aktie

Biogen: Positives zu Zuranolone - Aktienanalyse

Toronto (www.aktiencheck.de) - Biogen-Aktienanalyse von RBC Capital Markets: Brian Abrahams, Analyst vom Investmenthaus RBC Capital Markets, bewertet die Aktie von Biogen…

The VA Will Pay for Leqembi. Its a Step in Right Direction for Biogen.

The biotech and its partner Eisai are seeking to get Medicare to pay for the new Alzheimer's disease therapy....…

1 Reason to Buy Biogen Stock, and 1 Reason to Sell

It could be a make or break year for the biotech....…

Biogen Appoints Chuck Triano as Head of Investor Relations

CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced the appointment of Chuck…

Eisai sees Biogen-partnered Alzheimer’s therapy to bring over $7B sales in 2030

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $263.02, moving -0.7% from the previous trading session....…

Biogen elects new board chairperson

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors

CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced that the Board of…

FDA Will Weigh Full Approval for Alzheimers Drug. Why It Matters for Biogen Stock.

The drug already has accelerated approval. Full approval would open the door for Medicare to pay for the treatment for…

Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi

The FDA grants priority review to Biogen (BIIB) and Eisais sBLA seeking traditional approval of Alzheimers disease drug, Leqembi. The…

Roche-Tochter Genentech verklagt Biogen wegen Patentgebühren

Pharmabranche - Die amerikanische Roche-Tochter Genentech hat einem Bericht zufolge am Dienstag den Konkurrenten Biogen vor einem Bundesgericht in San…

Roche-Tochter Genentech verklagt Biogen wegen Patentgebühren

Die Roche-Tochter Genentech hat laut einem Bericht der Nachrichtenagentur Reuters am Dienstag den Konkurrenten Biogen vor einem Bundesgericht in San…

Genentech sues Biogen for royalties on blockbuster MS drug

...By Blake Brittain (Reuters) - Roches Genentech Inc sued Biogen......…

Biogen Says BLA For Lecanemab Gets Priority Review By NMPA In China

WESTON (dpa-AFX) - Eisai Co., Ltd. and Biogen Inc. (BIIB) Tuesday said the Biologics License Application (BLA) for lecanemab, has…

Biogen: Kursziel angehoben

New York (www.aktiencheck.de) - Rating-Update: Das Anlagevotum der Analysten von Morgan Stanley für die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN:…

Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights

U.S. neurologists increasingly favor Novartis MS portfolio, particularly Kesimpta EXTON, Pa., Feb. 17, 2023 /PRNewswire/ -- According to Biogens earnings…

Biogen: Kursziel gesenkt

Toronto (www.aktiencheck.de) - Rating-Update: Brian Abrahams, Analyst vom Investmenthaus RBC Capital Markets, bewertet die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN:…

Biogen: Kursziel erhöht

New York (www.aktiencheck.de) - Rating-Update: Philip Nadeau, Analyst von Cowen and Company, stuft die Biogen-Aktie (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP,…

INNOCARE-B Once Craters 30% after Biogen Terminates Collaboration & License Agreement

INNOCARE-B (09969.HK) opened lower by 14.9% this morning (16th), and has once nosedived 30.1% to bottom at $8.51, a fresh…

Biogen (BIIB) Q4 2022 Earnings Call Transcript

BIIB earnings call for the period ending December 31, 2022....…

Compared to Estimates, Biogen Inc. (BIIB) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for Biogen Inc. (BIIB) give a sense of how its business performed in the quarter…

Biogen CEO Viehbacher to Boost Investment in New Drugs for ...

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up

Biogen (BIIB) beats fourth-quarter estimates for earnings and sales. Stock rises in pre-market....…

Biogen expects new Alzheimer’s drug to weigh on 2023 outlook

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biogen Inc. (BIIB) Q4 Earnings and Revenues Beat Estimates

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.38% and 4.13%, respectively, for the quarter ended December 2022. Do…

Opening Bell: TripAdvisor, Airbnb, Tesla, Biogen, BioCryst

Die US-Inflationsdaten sorgten gestern für eine kleine Berg- und Talfahrt bei den US-Indizes. Am Ende ging der Dow Jones mit…

Opening Bell: Dow Jones startet im Minus; Einzelhandelsumsätze Januar, Biogen, Tripadvisor, Airbnb, Tesla, Biocryst im Fokus

Starke Einzelhandelsumsätze im Januar verunsichern am Mittwoch die Anleger an der Wall Street und drücken die Indizes ins Minus. 30…

Drugmaker Biogen tops 4Q forecasts despite sales slip

Biogen closed 2022 with a better-than-expected fourth quarter, as more cost cutting helped counter sales declines for some key treatments...…

Biogen Q4 Results Top Estimates

Biotechnology company Biogen Inc. reported Wednesday that profit for the fourth quarter surged 50 percent from last year, reflecting lower…

Biogen Q4 Results Top Estimates

WESTON (dpa-AFX) - Biotechnology company Biogen Inc. (BIIB) reported Wednesday that profit for the fourth quarter surged 50 percent from…

Biogen Inc. Q4 Profit Increases, beats estimates

WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced earnings for its fourth quarter that increased from the same period last year…

Biogen’s stock gains after company beats Q4 revenue and earnings expectations

Shares of Biogen Inc. BIIB gained about 1.7% in premarket trading on Wednesday after the company beat revenue and earnings…

Biogen beats Q4 top and bottom line estimates; initiates FY23 outlook

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biogen earnings beat estimates on boost from muscle disorder drug

...(Reuters) - Biogen Inc beat Wall Street expectations......…

Drugs for Alzheimers, Depression, Are in Focus as Biogen Reports Earnings

The expected rollouts of both drugs this year are vital to the company's future because its remaining offerings face intense…

Airbnb, Coca-Cola, Shopify, and More to Watch

The January consumer price index is out on Tuesday. Plus, earnings from Airbnb, Coca-Cola, Marriott, Biogen, Cisco, Shopify, DoorDash, Hasbro,…

FDA accepts NDA filing by Biogen and Sage for zuranolone

After granting priority review for the application, the FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of…

Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know

Biogen Inc. (BIIB) closed at $288.28 in the latest trading session, marking a +1.64% move from the prior day....…

Sage Therapeutics: FDA To Review NDA For Zuranolone

WESTON (dpa-AFX) - Sage Therapeutics, Inc. (SAGE) and Biogen Inc. (BIIB) announced the FDA has accepted the filing of a…

Biogen, Sage Get FDA Priority Review of Zuranolone >BIIB SAGE

Biogen, Sage Get FDA Priority Review of Zuranolone >BIIB SAGE...…

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced…

dpa-AFX ProFeed